ERBB2 and breast cancer: Among patients dying of HD, 9922 (43.6%) cases occurred within 5 years after the diagnosis of BC, and 7,350 (32.3%) cases within 5 to 10 years (Fig. 3); higher proportion of patients with TNBC and HER2-positive subtype died within 3 years compared to patients with HR+/HER2- BC (Fig. 4).